Manage settings
MENU
About this site
In het Nederlands
Home
Researchers
Projects
Organisations
Publications
Infrastructure
Contact
Research Explorer
Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.
Researcher
Sandra Van Lint
Profile
Projects
Publications
Activities
Awards & Distinctions
43
Results
2024
Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
Joline Ingels
Laurenz De Cock
Dieter Stevens
Rupert Mayer
Fabien Henri Thery
Guillem Sanchez Sanchez
David Vermijlen
Karin Weening
SASKIA DE SMET
NELE LOOTENS
et al.
A1
Journal Article
in
CELL REPORTS MEDICINE
2024
2023
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state
Sandra Van Lint
Alexander Van Parys
Bram Van Den Eeckhout
Niels Vandamme
Stephane Plaisance
Annick Verhee
Dominiek Catteeuw
Elke Rogge
Jennifer De Geest
Nele Vanderroost
et al.
A1
Journal Article
in
MOLECULAR CANCER
2023
2022
Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials
Joline Ingels
Laurenz De Cock
Rupert Mayer
Pam Devreker
Karin Weening
Kelly Heyns
Nele Lootens
Saskia De Smet
Marieke Brusseel
Stijn De Munter
et al.
A1
Journal Article
in
CYTOTHERAPY
2022
2021
Dendritic cell-based immunotherapy in lung cancer
Dieter Stevens
Joline Ingels
Sandra Van Lint
Bart Vandekerckhove
Karim Vermaelen
A1
Journal Article
in
FRONTIERS IN IMMUNOLOGY
2021
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication
Bram Van Den Eeckhout
Leander Huyghe
Sandra Van Lint
Elianne Burg
Stéphane Plaisance
Frank Peelman
Anje Cauwels
Gilles Uzé
Niko Kley
Sarah Gerlo
et al.
A1
Journal Article
in
JOURNAL FOR IMMUNOTHERAPY OF CANCER
2021
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE
Anje Cauwels
Sandra Van Lint
Elke Rogge
Annick Verhee
Bram Van Den Eeckhout
Shengru Pang
Marco Prinz
Niko Kley
Gilles Uze
Jan Tavernier
A1
Journal Article
in
SCIENTIFIC REPORTS
2021
mRNA in cancer immunotherapy : beyond a source of antigen
Lien Van Hoecke
Rein Verbeke
Heleen Dewitte
Ine Lentacker
Karim Vermaelen
Karine Breckpot
Sandra Van Lint
A1
Journal Article
in
MOLECULAR CANCER
2021
2020
Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies
Leander Huyghe
Alexander Van Parys
Anje Cauwels
Sandra Van Lint
Stijn De Munter
Jennyfer Bultinck
Lennart Zabeau
Jeroen Hostens
An Goethals
Nele Vanderroost
et al.
A1
Journal Article
in
EMBO MOLECULAR MEDICINE
2020
Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses
Bram Van Den Eeckhout
Lien Van Hoecke
Elianne Burg
Sandra Van Lint
Frank Peelman
Niko Kley
Gilles Uzé
Xavier Saelens
Jan Tavernier
Sarah Gerlo
C3
Conference
2020
Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant
Bram Van Den Eeckhout
Lien Van Hoecke
Elianne Burg
Sandra Van Lint
Frank Peelman
Niko Kley
Gilles Uzé
Xavier Saelens
Jan Tavernier
Sarah Gerlo
A1
Journal Article
in
NPJ VACCINES
2020
The opposing effect of type I IFN on the T cell response by non-modified mRNA-lipoplex vaccines Is determined by the route of administration
Lien Van Hoecke
Kenny Roose
Marlies Ballegeer
Zifu Zhong
Niek Sanders
Stefaan De Koker
Xavier Saelens
Sandra Van Lint
A1
Journal Article
in
MOLECULAR THERAPY-NUCLEIC ACIDS
2020
mRNA-based therapeutics to induce immunity against cancer and infectious diseases
Lien Van Hoecke
Xavier Saelens
Sandra Van Lint
Kenny Roose
Dissertation
2020
2019
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice
Anje Cauwels
Sandra Van Lint
Dominiek Catteeuw
Shengru Pang
Franciane Paul
Elke Rogge
Annick Verhee
Marco Prinz
Niko Kley
Gilles Uzé
et al.
A1
Journal Article
in
JOURNAL OF AUTOIMMUNITY
2019
Towards the use of interleukin-1β as vaccine adjuvant
Bram Van Den Eeckhout
Lien Van Hoecke
Elianne Burg
Sandra Van Lint
Frank Peelman
Xavier Saelens
Jan Tavernier
Sarah Gerlo
C3
Conference
2019
2018
Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments
Anje Cauwels
Sandra Van Lint
Franciane Paul
Genevieve Garcin
Stefaan De Koker
Alexander Van Parys
Thomas Wüest
Sarah Gerlo
José Van Der Heyden
Yan Bordat
et al.
A1
Journal Article
in
CANCER RESEARCH
2018
IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination
Bram Van Den Eeckhout
Elianne Burg
Anje Cauwels
Frank Peelman
Sandra Van Lint
Jan Tavernier
Sarah Gerlo
C3
Conference
2018
Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses
Lutz Nuhn
Stefaan De Koker
Sandra Van Lint
Zifu Zhong
João Portela Catani
Francis Combes
Kim Deswarte
Yupeng Li
Bart Lambrecht
Stefan Lienenklaus
et al.
A1
Journal Article
in
ADVANCED MATERIALS
2018
Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes
Lien Van Hoecke
Sandra Van Lint
Kenny Roose
Alexander Van Parys
Peter Vandenabeele
Johan Grooten
Jan Tavernier
Stefaan De Koker
Xavier Saelens
A1
Journal Article
in
NATURE COMMUNICATIONS
2018
2017
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
Anje Cauwels
Sandra Van Lint
Geneviève Garcin
Jennyfer Bultinck
Franciane Paul
Sarah Gerlo
José Van Der Heyden
Yann Bordat
Dominiek Catteeuw
Lode De Cauwer
et al.
A1
Journal Article
in
ONCOIMMUNOLOGY
2017
IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination
Bram Van Den Eeckhout
Elianne Burg
Anje Cauwels
Frank Peelman
Sandra Van Lint
Jan Tavernier
Sarah Gerlo
C3
Conference
2017
2016
Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells
Sandra Van Lint
Dries Renmans
Katrijn Broos
Lode Goethals
Sarah Maenhout
Daphné Benteyn
Cleo Goyvaerts
Stephanie Dufour
Kevin Van Der Jeught
Lukasz Bialkowski
et al.
A1
Journal Article
in
CANCER IMMUNOLOGY RESEARCH
2016
Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses
Ans De Beuckelaer
Charlotte Pollard
Sandra Van Lint
Kenny Roose
Lien Van Hoecke
Tom Naessens
Vimal Kumar Udhayakumar
Muriel Smet
Niek Sanders
Stefan Lienenklaus
et al.
A1
Journal Article
in
MOLECULAR THERAPY
2016
2015
Intratumoral delivery of mRNA : overcoming obstacles for effective immunotherapy
Kevin Van Der Jeught
Sandra Van Lint
Kris Thielemans
Karine Breckpot
A1
Journal Article
in
ONCOIMMUNOLOGY
2015
Microbubbles as magic bullets in cancer immunotherapy
Heleen Dewitte
Sandra Van Lint
Katrien Vanderperren
Hendrik Haers
Emmelie Stock
Stefaan De Smedt
Karine Breckpot
Ine Lentacker
C3
Conference
2015
Targeting the tumor microenvironment to enhance antitumor immune responses
Kevin Van Der Jeught
Lukasz Bialkowski
Lidia Daszkiewicz
Katrijn Broos
Cleo Goyvaerts
Dries Renmans
Sandra Van Lint
Carlo Heirman
Kris Thielemans
Karine Breckpot
A1
Journal Article
in
ONCOTARGET
2015
The ReNAissanCe of mRNA-based cancer therapy
Sandra Van Lint
Dries Renmans
Katrijn Broos
Heleen Dewitte
Ine Lentacker
Carlo Heirman
Karine Breckpot
Kris Thielemans
A1
Journal Article
in
EXPERT REVIEW OF VACCINES
2015
2014
Development of a local treatment modality for the systemic cure of cancer using mRNA as a medicinal product
Sandra Van Lint
Kris Thielemans
Karine Breckpot
Dissertation
2014
Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts
Sarah K Maenhout
Sandra Van Lint
Perpetua U Emegi
Kris Thielemans
Joeri L Aerts
A1
Journal Article
in
INTERNATIONAL JOURNAL OF CANCER
2014
Immunogenicity of targeted lentivectors
Cleo Goyvaerts
Kurt De Groeve
Sandra Van Lint
Carlo Heirman
Jo A Vanginderachter
Patrick De Baetselier
Geert Raes
Kris Thielemans
Karine Breckpot
A1
Journal Article
in
ONCOTARGET
2014
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
Sandra Van Lint
Sofie Wilgenhof
Carlo Heirman
Jurgen Corthals
Karine Breckpot
Aude Bonehill
Bart Neyns
Kris Thielemans
A1
Journal Article
in
CANCER IMMUNOLOGY IMMUNOTHERAPY
2014
The bubble breakthrough in cancer immunotherapy
Heleen Dewitte
Sandra Van Lint
Katrien Vanderperren
Stefaan De Smedt
Karine Breckpot
Ine Lentacker
C3
Conference
2014
The bubble breakthrough in cancer immunotherapy : Mma-sonoporation in dendritic cell-based cancer vaccination
Heleen Dewitte
Sandra Van Lint
Katrien Vanderperren
Kris Thielemans
Stefaan De Smedt
Karine Breckpot
Ine Lentacker
C3
Conference
2014
The bubble breakthrough in cancer immunotherapy : Mma-sonoporation in dendritic cell-based cancer vaccination
Heleen Dewitte
Sandra Van Lint
Katrien Vanderperren
Kris Thielemans
Stefaan De Smedt
Karine Breckpot
Ine Lentacker
C3
Conference
2014
The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy
Heleen Dewitte
Sandra Van Lint
Carlo Heirman
Kris Thielemans
Stefaan De Smedt
Karine Breckpot
Ine Lentacker
A1
Journal Article
in
JOURNAL OF CONTROLLED RELEASE
2014
2013
Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo
Daphné Benteyn
Sébastien Anguille
Sandra Van Lint
Carlo Heirman
An MT Van Nuffel
Jurgen Corthals
Sebastian Ochsenreither
Wim Waelput
Katrien Van Beneden
Karine Breckpot
et al.
A1
Journal Article
in
MOLECULAR THERAPY-NUCLEIC ACIDS
2013
Priming of cytotoxic T lymphocyte responses by dendritic cells: induction of potent anti-tumor immune responses
Sandra Van Lint
An MT van Nuffel
Sofie Wilgenhof
Daphné Benteyn
Joeri Pen
David Escors
Aude Bonehill
Bart Neyns
Kris Thielemans
Karine Breckpot
Bookchapter
in
Horizons in Cancer Research, vol. 51
2013
mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic
Sandra Van Lint
Carlo Heirman
Kris Thielemans
Karine Breckpot
Editorial material
2013
2012
Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells
Cleo Goyvaerts
Kurt De Groeve
Jozef Dingemans
Sandra Van Lint
Lander Robays
Carlo Heirman
J Reiser
Kris Thielemans
Patrick De Baetselier
Geert Raes
et al.
A1
Journal Article
in
GENE THERAPY
2012
Preclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy
Sandra Van Lint
Cleo Goyvaerts
Sarah Maenhout
Lode Goethals
Aurélie Disy
Daphné Benteyn
Joeri Pen
Aude Bonehill
Carlo Heirman
Karine Breckpot
et al.
A1
Journal Article
in
CANCER RESEARCH
2012
Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy
Perpetua U Emeagi
Sandra Van Lint
Cleo Goyvaerts
Sarah Maenhout
Anje Cauwels
Lain A McNeish
Tomas Bos
Carlo Heirman
Kris Thielennans
Joeri L Aerts
et al.
A1
Journal Article
in
CANCER RESEARCH
2012
2011
mRNA: delivering an anti-tumor message?
Sandra Van Lint
Kris Thielemans
Karine Breckpot
A1
Journal Article
in
IMMUNOTHERAPY
2011
2010
HIV-1 Lentiviral vector immunogenicity is mediated by Toll-Like Receptor 3 (TLR3) and TLR7
Karine Breckpot
David Escors
Frederic Arce
Lucienne Lopez
Katarzyna Karwacz
Sandra Van Lint
Marleen Keyaerts
Mary Collins
A1
Journal Article
in
JOURNAL OF VIROLOGY
2010
Large double copy vectors are functional but show a size-dependent decline in transduction efficiency
Tomas J Bos
Sandra Van Lint
Carlo Heirman
Karin Vanderkerken
A1
Journal Article
in
JOURNAL OF BIOTECHNOLOGY
2010